2 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 suspended. 4 Phase 2, 3 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 3 | Not yet recruiting 1, Recruiting 1, Suspended 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Refractory Hepatocellular Carcinoma: new trials by email Literature Review of Refractory Hepatocellular Carcinoma trials Research Report on Refractory Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure JDB153, Penpulimab - Refractory Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 10 | 2025-08-01 | 2025-07-20 |
| Ligufalimab and Cadonilimab in Advanced Liver Cancers Ligufalimab, Cadonilimab - Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 64 | 2025-02-18 | 2026-02-27 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Nanoplexed Poly I:C BO-112, Pembrolizumab - Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Early Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2021-10-13 | 2023-03-24 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
Carcinoma, Hepatocellular (6) · Hepatoblastoma (2) · Osteosarcoma (2) · Sarcoma, Ewing (2) · Wilms Tumor (2) · Adrenocortical Carcinoma (1) · Biliary Tract Neoplasms (1) · Carcinoma, Medullary (1) · Carcinoma, Renal Cell (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Desmoid Tumors (1) · Endometrial Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1)
Adenocarcinoma (6) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Liver Diseases (6) · Liver Neoplasms (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
Specimen Handling (2) · Absorptiometry, Photon (1) · BO-112 (1) · Bone Density (1) · Cyclophosphamide (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · X-Rays (1) · cabozantinib (1) · fludarabine (1) · pembrolizumab (1) · penpulimab (1)
Children's Oncology Group (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Texas Southwestern Medical Center (1) · West China Hospital (1)
United States (5)
Anuradha Krishnamurthy (1) · David Hsieh, MD (1) · Richard S Finn (1) · Sarah B Whittle (1) · Srivandana Akshintala (1)
U10CA180886 (1), UM1CA228823 (1)